Novara Biotech reports quarterly revenue above the internal plan
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
Novara Biotech
Healthcare · Biotechnology
Updated UTC
410.77 US$
+5.46+1.35%
After hours412.82 US$+0.50%
| Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 31.67 مليار | 37.26 مليار | 41.96 مليار | 48.31 مليار | 53.67 مليار |
| Gross profit | 18.76 مليار | 21.53 مليار | 23.9 مليار | 26.46 مليار | 32.34 مليار |
| Operating income | 6.26 مليار | 7.62 مليار | 7.85 مليار | 9.58 مليار | 11.72 مليار |
| Net income | 4.88 مليار | 5.63 مليار | 6.17 مليار | 5.78 مليار | 7.65 مليار |
Clinical-stage developer of oral therapies for autoimmune and metabolic disorders.
Novara Biotech said demand in its Biotechnology segment held up through the quarter, with management reiterating full-year margin guidance.
Sector Desk
The company approved a multi-year capital program intended to shorten lead times for its largest customers.
Sector Desk
A sell-side desk kept a neutral rating while noting that near-term estimates already reflect steady execution.
Sector Desk
The board named an internal candidate with prior treasury and investor-relations experience to the role.
Sector Desk
The authorization covers a modest slice of the float and will be funded from operating cash flow.
Terminal Brief